Science Corporation implants its vision-restoring chip in its first Stargardt disease patient

What happened: Science Corporation implanted its PRIMA vision chip in its first Stargardt disease patient, CEO Max Hodak said at TechCrunch Disrupt. The patient received the implant in May at Sydney Eye Hospital in Australia. Key numbers: About 150,000 people worldwide have lost vision to Why it matters: PRIMA is already commercially available in Europe for geographic atrophy, and the company believes the approach can extend to multiple diseases, including Stargardt, which is currently considered incurable. Hodak said the company aims to approach native acuity over the next five years.

Science Corporation implanted its PRIMA vision chip in its first Stargardt disease patient, CEO Max Hodak said at TechCrunch Disrupt. The patient received the implant in May at Sydney Eye Hospital in Australia.

PRIMA is already commercially available in Europe for geographic atrophy, and the company believes the approach can extend to multiple diseases, including Stargardt, which is currently considered incurable. Hodak said the company aims to approach native acuity over the next five years.